MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$1,837K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net loss/(gain) on disposal of a...
    • Accounts payable
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Gain on the termination of an op...
    • Operating lease liabilities
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Amortization of bond premium
-
-
0
-
Impairment charges of goodwill and other intangible assets
-
-
0
-
Impairment charges of other assets
-
-
0
-
Net loss
-1,326
-1,921
-1,912
-1,532
Income tax benefit
-
-
0
-
Depreciation and amortization
-
0
3
-1
Net loss/(gain) on disposal of assets
-248
-
-
0
Change in fair value of warrant liability
-
0
0
0
Stock-based compensation expense
104
113
217
253
Change in operating lease right-of-use assets
3
74
91
111
Change in finance lease right-of-use assets
1
0
1
1
Net gain on disposal of assets
-
-
37
-
Gain on the termination of an operating lease
368
-
-
-
Loss on operating lease right-of-use assets modification
-
-
241
-
Operating lease liabilities
-365
-165
-484
-195
Prepaid expenses and other current assets
-35
341
-141
-205
Accounts payable
132
397
235
-86
Accrued expenses and other liabilities
-190
242
-115
-230
Net cash used in operating activities
-1,836
-1,601
-1,509
-1,474
Purchases of marketable debt securities
-
-
0
-
Proceeds from sales of marketable debt securities
-
-
0
-
Proceeds from sale of assets
-
-
15
320
Net cash provided by (used in) investing activities
-
0
15
320
Net proceeds from public offerings of common stock and warrants
-
-
0
-
Gross proceeds from private placement of preferred stock and common stock warrants
-
0
0
0
Transaction costs paid pursuant to private placement
-
0
0
0
Net proceeds from exercise of warrants
-
-
65
64
Payments of finance lease liability principal
1
0
7
0
Net cash (used in) provided by financing activities
-1
0
58
64
Net decrease in cash, cash equivalents and restricted cash
-
-1,601
-1,436
-
Net decrease in cash, cash equivalents and restricted cash
-1,837
-1,601
-1,436
-1,090
Cash, cash equivalents and restricted cash at beginning of period
2,648
4,249
5,685
7,534
Cash, cash equivalents and restricted cash at end of period
811
2,648
4,249
5,685
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net decrease incash, cash...-$1,837K (-142.03%↓ Y/Y)Net loss/(gain) ondisposal of assets-$248K (-325.45%↓ Y/Y)Accounts payable$132K (85.92%↑ Y/Y)Stock-based compensationexpense$104K (-81.19%↓ Y/Y)Prepaid expenses andother current assets-$35K (89.03%↑ Y/Y)Change in operatinglease right-of-use...$3K (-98.62%↓ Y/Y)Change in finance leaseright-of-use assets$1K (-50.00%↓ Y/Y)Net cash used inoperating activities-$1,836K (54.42%↑ Y/Y)Net cash (used in)provided by financing...-$1K (-100.03%↓ Y/Y)Canceled cashflow$523K Net loss-$1,326K (80.79%↑ Y/Y)Gain on thetermination of an operating...$368K Operating leaseliabilities-$365K (-0.55%↓ Y/Y)Payments of finance leaseliability principal$1K (-50.00%↓ Y/Y)Accrued expenses andother liabilities-$190K (81.15%↑ Y/Y)something is missing-$110K

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. (MTNB)